In prostate cancer, Hu et al. revealed that TPL treatment increased the expression of death receptor 5 (DR5), rendering cancer cells significantly sensitive to apoptosis mediated by TRAIL [64]. Here, TNFRSF10B is linked to prostate carcinoma.